One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Relay Therapeutics logo
Relay Therapeutics RLAY
$ 16.28 1.41%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Relay Therapeutics Cash Flow 2025-2011 | RLAY

Brief overview of Relay Therapeutics's cash flow quality

Cash flow changes are traced through the five latest available reports from 2020 to 2024.

Cash from operations is below zero at -$249.1 million, increasing dependence on cash reserves or outside financing.

Only 0 of five observations were above zero. The business relies heavily on individual strong periods.

What the cash flows show

Relay Therapeutics's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.

Annual Cash Flow Relay Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-235 M -249 M -300 M -229 M -74.4 M -102 M -66.1 M - - - - - - - -

Depreciation & Amortization

3.56 M 5.46 M 5.27 M 4.13 M 3.92 M 3.55 M 2.84 M - - - - - - - -

Accounts Payables

7.7 M 14.1 M 9.21 M 10.6 M 8.28 M 6.35 M - - - - - - - - -

Accounts Receivables

- - - 306 K 403 K 75 M - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Relay Therapeutics

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-105 M -51.1 M - - - -73.2 M - - - -50.3 M - - - -67.1 M - -172 M - -49.2 M - -34.7 M - 46.6 M - -67.2 M -43.2 M -22.3 M - -43.4 M -25.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

864 K 504 K - - - 1.21 M - - - 1.4 M - - - 1.2 M - 2.96 M - 975 K - 2.89 M - 919 K - 2.64 M 1.72 M 859 K - 1.99 M 1.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

11.5 M 4.1 M 7.7 M 2.75 M 5.18 M 8.45 M 14.1 M 6.87 M 11.2 M 7.97 M 9.21 M 13.4 M 14.8 M 11.8 M 10.6 M 9.48 M - 8.05 M 8.28 M 6.32 M 7.87 M 5.59 M 6.35 M 6.35 M 6.35 M 6.35 M 6.99 M 6.99 M 6.99 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

- - - - - - - - - - - 211 K 78 K 286 K 306 K 241 K - 269 K 403 K 804 K 279 K - 75 M 75 M 75 M 75 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Relay Therapeutics, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Seres Therapeutics Seres Therapeutics
MCRB
$ 2.46 1.19 % $ 21.8 M usaUSA
Precigen Precigen
PGEN
$ 6.39 0.54 % $ 2 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 4.72 1.45 % $ 77.2 M israelIsrael
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 2.18 6.79 % $ 242 M usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 7.67 0.13 % $ 1.06 B usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 14.63 1.59 % $ 10.9 B britainBritain
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 39.9 2.63 % $ 4.58 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.05 0.95 % $ 112 M britainBritain
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada